



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc



Inhibition of proteasome activity by anthocyanins and anthocyanidins

Andrea Dreiseitel ^{a,*}, Peter Schreier ^b, Anett Oehme ^b, Sanja Locher ^b, Gerhard Rogler ^{c,d}, Heidi Piberger ^c, Goeran Hajak ^a, Philipp G Sand ^a

^a Department of Psychiatry, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany

^b Chair of Food Chemistry, University of Wuerzburg, Am Hubland, 97074 Wuerzburg, Germany

^c Department of Internal Medicine I, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany

^d Department of Internal Medicine, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland

ARTICLE INFO

Article history:

Received 27 November 2007

Available online 5 May 2008

Keywords:

Proteasome
Anthocyanin
Anthocyanidin
Procyanidin
Flavonoid

ABSTRACT

Recent reports have demonstrated multiple benefits associated with the consumption of berry fruits, including a decreased vulnerability to oxidative stress, reduced ischemic brain damage, protection of neurons from stroke-induced damage and the reversal of age-related changes in brain and behaviour. Berry fruits contain high amounts of anthocyanins, which play a major role as free radical scavengers. The present study addresses proteasome inhibition as a further mechanism by which anthocyanins and their aglycons, the anthocyanidins, may exert health-promoting effects. HL-60 cells were incubated with 19 test substances and inhibition of the chymotrypsin-like enzyme activity was determined in a chemiluminescent assay. Anthocyanins and their aglycons achieved IC₅₀ values ranging from 7.8 μM for kaempferidinidin and pelargonidin, to 32.4 μM for delphinidin. Thus proteasome inhibitory properties of anthocyanins may contribute to their known anticarcinogenic, antioxidative, anti-inflammatory and neuroprotective activities, rationalizing dietary supplementations with anthocyanins in the prevention and treatment of chronic diseases, including neurodegenerative disorders.

© 2008 Elsevier Inc. All rights reserved.

Over the past decade, awareness has increased of multiple health-promoting effects of anthocyanins, powerful antioxidants that confer the characteristic red, blue, and purple colours to many dietary plants [1]. Anthocyanins are water-soluble, glycosidic polyhydroxyl, and polymethoxyl derivatives of flavylum salts and are most abundant in berries, grapes, and red cabbage, among other foodstuffs. When expressed per 100 g fresh weight, approximately 1480 mg of anthocyanins may be obtained from chokeberries [2], 588 mg from bilberries [3], 476 mg from black currant and 322 mg from red cabbage [2]. The average dietary per capita and day consumption of anthocyanins was originally estimated at 180–215 mg in Western societies [4]. More recent calculations from U.S. American surveys have concluded to a daily intake of only 12.5 mg [2], but the actual amount has been shown to vary considerably with sociodemographic and life-style factors [5], plus the seasonal availability of anthocyanin-rich fruits and vegetables [2].

Health benefits associated with diets rich in anthocyanins are ascribed to multi-level biological activities including antioxidative

[6], anti-inflammatory [7], antiviral [8], vasoprotective [9], antiangiogenic [10], and anticarcinogenic effects [11]. In animals, blueberry-enriched diets protect neurons from ischemia-induced damage, decrease the vulnerability to oxidative stress and improve motor function [12]. It has been proposed that consumption of fruits rich in anthocyanins may protect against age-related deficits and may mitigate existing deficits with regard to central nervous system function [13,14]. In humans, epidemiological findings and placebo-controlled trials indicate that anthocyanins can reduce mortality from cardiovascular and coronary heart disease [15], can aid in the management of diabetic retinopathy [16] and can improve dark adaptation [17]. However, despite the spectrum of pharmacological effects elicited by anthocyanins, information on the underlying cellular mechanisms is scarce. We hypothesized that the proteasome may be targeted by anthocyanins based on data from apple and grape extracts [18]. Proteasome activity controls the degradation of cellular proteins and is closely implicated in signal transduction, development, cell cycle progression [19], antigen processing, immune response [20], and inflammation [21] plus protection from oxidative stress [22] relevant to neurodegenerative diseases [23,24]. The present study was conceived to examine anthocyanins', anthocyanidins', and proanthocyanidins' in vitro impact on the chymotrypsin-like (ChT-L) proteasome activity.

Abbreviations: ChT-L, chymotrypsin-like; DMEM, Dulbecco's modified Eagle Medium; HSP, heat shock protein; NF-κB, nuclear factor κB.

* Corresponding author. Fax: +49 941 944 8956.

E-mail address: andrea.dreiseitel@klinik.uni-regensburg.de (A. Dreiseitel).

Experimental methods

Chemicals. L-glutamine (200 mM) and Dulbecco's modified Eagle Medium (DMEM, 4.5 g/l glucose, sodium pyruvate, 3.7 g/l NaHCO₃, without L-glutamine) were purchased from Pan Biotech GmbH (Aidenbach, Germany), FCS from Gibco BRL Life Technologies (Eggenstein, Germany) and penicillin-streptomycin (10,000 units/10 ml) from PAA Laboratories GmbH (Coelbe, Germany). Proteasome Glo Cell-Based Assay was obtained from Promega (Mannheim, Germany). Cyanidin, cyanidin-3,5-diglucoside (cyanin), cyanidin-3-galactoside (ideain), cyanidin-3-glucoside (kuromanin), cyanidin-3-rutinoside (keracyanin), delphinidin, delphinidin-3-glucoside (myrtillin), kaempferidinidin, malvidin, malvidin-3,5-diglucoside (malvin), malvidin-3-galactoside, malvidin-3-glucoside (oenin), peonidin, peonidin-3-glucoside, pelargonidin, pelargonidin-3,5-diglucoside (pelargonin), petunidin, procyanidin B1, and procyanidin B2 were purchased from Extrasynthese (Genay, France). All test substances were dissolved and diluted in DMSO.

Cell culture. HL-60 cells were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). Cells were cultured in DMEM supplemented with 10% (v/v) foetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin plus 100 µg/ml streptomycin, and were maintained in an atmosphere of 5% CO₂ at a temperature of 37 °C. Passages were carried out every three days. For the assay, an aliquot of the cell suspension was drawn from the cell culture flask and centrifuged at 1200 rpm for five minutes. The supernatant was removed and the cell pellet was resuspended in the culturing medium.

Inhibition of chymotrypsin-like activity in human cells by flavonoids. Effects of the test substances on the proteasomal chymotrypsin-like activity were determined using a chemiluminescent assay (Proteasome Glo Cell-Based Assay, Promega). HL-60 cells were dispensed into white opaque 96-well microtiter plates, at a density of 1×10^4 cells in 100 µl culturing medium per well. Instantly, 1 µl of flavonoid, diluted in DMSO, was added to the culturing medium. An equivalent volume of DMSO was used as a negative control. After incubation at room temperature for 7 min, 100 µl assay buffer, containing the luminogenic proteasome substrate succinyl-leucine-leucine-valine-tyrosine-aminoluciferin and a recombinant firefly luciferase were added. Subsequent to further incubation at room temperature for 7 min, chemiluminescence, expressed as relative light units (RLU), was measured on an Anthos Lucy 1 microplate luminometer (Anthos Labtech, Salzburg, Austria) with a measuring time of 12 s for each well. Anthocyanins, anthocyanidins, and procyanidins were diluted with DMSO to yield final concentrations of 2, 5, 10, 50, and 100 µmol/l in the assay.

Data analysis. To quantify proteasome inhibition by our test substances, the chymotrypsin-like (ChT-L) activity of the proteasome was obtained using a coupled-enzyme system, with proteasome cleavage of the substrate releasing aminoluciferin and a luciferase reaction generating a chemiluminescence signal. Chymotrypsin-like activity was calculated according to the following equation:

$$\%A = 100 \times \left(1 - \frac{A_i}{A_{\text{DMSO}}} \right)$$

Where %A is the percentage of the ChT-L activity of the proteasome remaining after treatment with test substances, A_i is the activity of the chymotryptic site in the presence of an inhibitor, and A_{DMSO} is the activity of the proteasome in the absence of inhibitors.

For each substance tested, mean values from three separate experiments performed in triplicate at five concentrations were analyzed with Prism v. 2.01 (GraphPad Software, CA, USA) using a non-linear regression model to determine the concentrations

inhibiting 50% of the chymotrypsin-like proteasome activity (IC₅₀ values). Mean IC₅₀ values for anthocyanins and anthocyanidins were compared using *t*-tests. Statistical significance was set at *p* = 0.05. ISIS/Draw v. 2.1.4 (MDL Information Systems, CA, USA) served to create structures of anthocyanins and anthocyanidins.

Results

Table 1 summarizes IC₅₀ values of all flavonoids under study (Fig. 1). Across all compounds investigated, inhibition of the proteasomal chymotrypsin-like activity differed by a factor of 4. Anthocyanins and their aglycons inhibited proteasome activity in a concentration-dependent manner and achieved IC₅₀ values between 7.8 and 32.4 µM. Overall, the anthocyanidins kaempferidinidin, pelargonidin, and peonidin acted as powerful inhibitors with IC₅₀ values of 7.8, 7.8, and 9.0 µM, respectively. In the order of decreasing potency, cyanidin-3,5-diglucoside, cyanidin-3-glucoside, peonidin-3-glucoside, delphinidin-3-glucoside, cyanidin-3-galactoside, malvidin-3,5-diglucoside, cyanidin-3-rutinoside, cyanidin, malvidin-3-galactoside, malvidin-3-glucoside, and petunidin gave IC₅₀ values from 11.0 to 23.7 µM. The least potent inhibitors were identified as malvidin, pelargonidin-3,5-diglucoside, and delphinidin, featuring IC₅₀ values above 30 µM. When compounds were grouped according to the presence or the absence of a sugar moiety, no trend was seen with regard to proteasome inhibition. Mean IC₅₀ values of anthocyanins (IC₅₀ = 17.5 µM ± 6.6) and anthocyanidins (IC₅₀ = 18.7 µM ± 11.0) showed only a marginal difference (*p* = 0.78, *t* = 0.28, Table 1). This finding is further illustrated by the inhibitory profiles of the two anthocyanins, pelargonidin-3,5-diglucoside, and delphinidin-3-glucoside, and their corresponding aglycons (Fig. 2). For the first pair of compounds, pelargonidin, the aglycon, acted as a powerful proteasome inhibitor (IC₅₀ = 7.8 µM), whereas pelargonidin-3,5-diglucoside showed more moderate inhibition (IC₅₀ = 32.3 µM). For the second pair, however, inhibition by the aglycon delphinidin was less pronounced (IC₅₀ = 32.4 µM) than that achieved by the corresponding delphinidin-3-glucoside (IC₅₀ = 13.0 µM).

Table 1

Inhibition of proteasomal chymotrypsin-like activity in HL-60 cells by anthocyanins and anthocyanidins

Anthocyanin/anthocyanidin	IC ₅₀ in µM (anthocyanidins)	IC ₅₀ in µM (anthocyanins)
Kaempferidinidin	7.8	
Pelargonidin	7.8	
Peonidin	9.0	
Cyanidin-3,5-diglucoside (cyanin)		11.0
Cyanidin-3-glucoside (kuromanin)		12.6
Peonidin-3-glucoside		12.8
Delphinidin-3-glucoside (myrtillin)		13.0
Cyanidin-3-galactoside (ideain)		13.5
Malvidin-3,5-diglucoside (malvin)		17.1
Cyanidin-3-rutinoside (keracyanin)		18.1
Cyanidin	18.4	
Malvidin-3-galactoside		21.7
Malvidin-3-glucoside (oenin)		23.2
Petunidin	23.7	
Malvidin	32.0	
Pelargonidin-3,5-diglucoside (pelargonin)		32.3
Delphinidin	32.4	
Mean IC ₅₀ value ± SD	18.7 ± 11.0	17.5 ± 6.6
<i>p</i> (t, df)	0.80 (0.28, 15)	

For procyanidins B1 and B2, no inhibitory activity was observed. Only a marginal difference was noted in mean IC₅₀ values of anthocyanins and anthocyanidins (*p* = 0.78). Data are based on three separate experiments, each performed in triplicate.




Fig. 1. Chemical structures of tested anthocyanidins (A) and the epicatechin–epicatechin dimers procyanidins B1 and B2 (B).

For the procyanidin dimers B1 and B2, no inhibitory effects on proteasome activity were observed at any of the concentrations tested.

Discussion

Anthocyanins' anti-inflammatory, anticarcinogenic, and neuroprotective potencies have been ascribed to radical scavenging effects [25], the interaction with signalling cascades [26], age-related changes in adrenergic and noradrenergic receptor function [27], the enhancement of dopamine release [14] and shifts in cerebrovascular permeability [28]. In continuation of earlier research that focused on the inhibition of proteasome activity by grape extract [18], the present study explored the effects of anthocyanins and procyanidins, as well as the anthocyanins' aglycons. Our data confirm that the proteasome inhibitory activity of grape extract is at least in part mediated by anthocyanins and suggest that anthocyanin concentration may aid in predicting the activity of other fruit and vegetable extracts. Using the chymotryptic site of the proteasome in HL-60 cells, a concentration-dependent inhibition was shown with IC₅₀ values in the low micromolar range, with the exception of procyanidins which did not act as inhibitors. The anthocyanins and their aglycons achieve IC₅₀ values comparable to those of other flavonoids. For the flavon apigenin, the flavonols quercetin, kaempferol, and myricetin [29], and the tea flavanol (–)-epigallocatechin-3-gallate (EGCG) [30], IC₅₀ values range from

1 to 18 μM. Although the absence of sugar moieties from these flavonoids would appear to suggest a higher inhibitory potency of aglycons, this cannot be confirmed by our results (Table 1). Regarding the substitution-pattern of the anthocyanins' B-ring, mixed effects were noted on proteasome inhibition. Since the majority of effective inhibitors carry only one, or two, hydroxyl- or methoxyl-substituents on their B-ring, as opposed to three substituents in most of the remaining compounds, we assume that inhibitory potency may be sensitive to this structural feature.

For the dimeric procyanidins B1 and B2, the absence of effects in the present study does not imply that these substances cannot inhibit the proteasome. The chymotrypsin-like activity is generally considered the rate-limiting activity in protein breakdown [31], but dimeric procyanidins may inhibit other catalytically active sites of the proteasome, e.g. the "tryptic-like" or the "postglutamyl hydrolyzing" activity [32], or may exhibit proteolytic activities independent of the proteasome [33].

It should also be noted that cells were permeabilized to minimize any impact of transport parameters on measurements of proteasome inhibition. Only few data are currently available on cellular uptake of anthocyanins which limits extrapolations to in vivo effects [34].

Following oral intake and absorption in the intestine mostly as glycosides [35], up to 140 nmol/l of unconjugated anthocyanins are found in human plasma [36]. Anthocyanins and their corresponding aglycons are also found in animal brains within minutes after oral uptake [37,38]. In the present investigation, incubation time was kept short to avoid degradation of compounds.

Clinical applications of proteasome inhibition have focused on tumor suppression [39], a growing body of evidence supports additional roles in neuroprotection, e.g., dietary blueberry supplementation has been shown to elicit neuroplasticity in the hippocampus, and to improve cognitive performance [40]. Among the downstream effects already identified counts the upregulation of heat shock proteins (HSP) [41], and of enzymes involved in antioxidant defense [42], plus the suppression of the proinflammatory immune response [43]. Specifically, the expression levels of HSP22 and HSP70 are increased following proteasome inhibition [44], which is believed to prevent protein misfolding and the formation of protein aggregates. These cytoprotective qualities allow cells to survive under otherwise lethal conditions [45] and may slow the course of neurodegenerative disorders by refolding denatured proteins, as shown in models of Huntington's disease [46].

Furthermore, multiple antioxidant enzymes have been shown to be highly expressed following proteasome inhibition, including superoxide dismutase I [42], thioredoxin reductase I, peroxiredoxins I and VI, and metallothioneins I and II [44]. Moreover, it has been demonstrated that proteasomal inhibition affords cytoprotection against oxidative stress by inducing glutathione synthesis in animal models of Parkinson's disease [22]. Of all organs, the brain is most susceptible to oxidative damage due to its high oxygen demand [47]. Here, by protecting against oxidative and nitrosative stress [48,49], anthocyanins and anthocyanidins likely limit damage of brain cells at the protein, membrane lipid, and DNA levels. Finally, inhibitors of the proteasome affect the immune response by repressing antigen presentation on MHC class I receptors [50], by suppressing cytokine secretion, cell-cell-interaction, migration and chemotaxis of lymphocytes, and by inducing apoptosis in activated T-cells. Downregulation of cytokine secretion [51] and cell adhesion molecule expression [52] occurs via nuclear factor κB (NF-κB) inactivation [24]. It is suggested that activation of the NF-κB pathway may play a role in a number of acute and chronic diseases with an inflammatory component, such as atherosclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease [53], and neurodegenerative disorders such as cerebrovascular disease, Parkinson's disease, and Alzheimer's disease. In line with this




Fig. 2. Concentration-dependent inhibition of the chymotrypsin-like proteasome activity by pelargonidin, delphinidin, and the respective glucosides, pelargonidin-3,5-diglucoside, and delphinidin-3-glucoside: HL-60 cells were incubated with increasing amounts of test compounds for 7 min. Proteasome activity is expressed as relative residual activity of control cells treated with an equivalent volume of DMSO (100 %). Data points are means with standard deviation shown as vertical error bars of three independent experiments performed in triplicate. IC_{50} values were calculated from dose-response curves using non-linear regression.

assumption, rats fed a blueberry diet showed a decline in age-related cognitive deficits and a reduction in NF- κ B expression compared to non-supplemented controls [13,54]. It appears that rapidly dividing cells are more sensitive to pro-apoptotic effects of proteasome inhibitors than differentiated or non-proliferating cells [55], which can be advantageous in tumor therapy. Thus dietary supplementation with anthocyanins may serve to prevent a number of common diseases by interfering with the proteasome pathway.

In summary, inhibition of the proteasome by anthocyanins and anthocyanidins adds to our understanding of cellular effectors that may control anti-inflammatory, immunomodulatory, and neuroprotective activities of these substances. Further research is invited to address the mechanisms further downstream, and specifically, the contribution made by anthocyanin metabolites to a healthy diet.

Acknowledgments

This investigation was funded by the German Federal Ministry of Education, Science, Research and Technology, BMBF#0313848. We gratefully acknowledge helpful discussions with Dr. G. Krammer and Dr. J. Ley, Symrise GmbH & Co. KG, Holzminden.

References

- [1] B. Winkel-Shirley, Biosynthesis of flavonoids and effects of stress, *Curr. Opin. Plant Biol.* 5 (2002) 218–223.
- [2] X. Wu, G.R. Beecher, J.M. Holden, D.B. Haytowitz, S.E. Gebhardt, R.L. Prior, Concentrations of anthocyanins in common foods in the United States and estimation of normal consumption, *J. Agric. Food Chem.* 54 (2006) 4069–4075.
- [3] N. Nyman, J.T. Kumpulainen, Determination of anthocyanidins in berries and red wine by high-performance liquid chromatography, *J. Agric. Food Chem.* 49 (2001) 4183–4187.
- [4] J. Kühnau, The flavonoids. A class of semi-essential food components: their role in human nutrition, *World Rev. Nutr. Diet* 24 (1976) 117–191.
- [5] O.K. Chun, S.J. Chung, W.O. Song, Estimated dietary flavonoid intake and major food sources of U.S. adults, *J. Nutr.* 137 (2007) 1244–1252.
- [6] W. Zheng, S.Y. Wang, Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries, *J. Agric. Food Chem.* 51 (2003) 502–509.
- [7] H. Wang, M.G. Nair, G.M. Strasburg, Y.C. Chang, A.M. Booren, Antioxidant and antiinflammatory activities of anthocyanins and their aglycon, cyanidin, from tart cherries, *J. Nat. Prod.* 62 (1999) 294–296.
- [8] Y.M. Knox, K. Hayashi, T. Suzutani, M. Ogasawara, I. Yoshida, R. Shiina, A. Tsukui, N. Terahara, M. Azuma, Activity of anthocyanins from fruit extract of *Ribes nigrum* L. against influenza A and B viruses, *Acta Virol.* 45 (2001) 209–215.
- [9] M.C. Lazzè, R. Pizzala, P. Perucca, O. Cazzalini, M. Savio, L. Forti, V. Vannini, L. Bianchi, Anthocyanidins decrease endothelin-1 production and increase endothelial nitric oxide synthase in human endothelial cells, *Mol. Nutr. Food Res.* 50 (2006) 44–51.
- [10] S. Roy, S. Khanna, H.M. Alessio, J. Vider, D. Bagchi, M. Bagchi, C.K. Sen, Anti-angiogenic property of edible berries, *Free Radic. Res.* 36 (2002) 1023–1031.
- [11] D.X. Hou, Potential mechanisms of cancer chemoprevention by anthocyanins, *Curr. Mol. Med.* 3 (2003) 149–159.
- [12] M.I. Sweeney, W. Kalt, S.L. MacKinnon, J. Ashby, K.T. Gottschall-Pass, Feeding rats diets enriched in lowbush blueberries for six weeks decreases ischemia-induced brain damage, *Nutr. Neurosci.* 5 (2002) 427–431.
- [13] R.L. Galli, D.F. Bielinski, A. Szprengiel, B. Shukitt-Hale, J.A. Joseph, Blueberry supplemented diet reverses age-related decline in hippocampal HSP70 neuroprotection, *Neurobiol. Aging* 27 (2006) 344–350.
- [14] J.A. Joseph, B. Shukitt-Hale, N.A. Denisova, D. Bielinski, A. Martin, J.J. McEwen, P.C. Bickford, Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation, *J. Neurosci.* 19 (1999) 8114–8121.
- [15] P.J. Mink, C.G. Scrafford, L.M. Barraj, L. Harnack, C.P. Hong, J.A. Nettleton, D.R. Jacobs Jr., Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women, *Am. J. Clin. Nutr.* 85 (2007) 895–909.

- [16] R. Boniface, A.M. Robert, Effect of anthocyanins on human connective tissue metabolism in the human, *Klin. Monatsbl. Augenheilkd.* 209 (1996) 368–372.
- [17] H. Nakaishi, H. Matsumoto, S. Tominaga, M. Hirayama, Effects of black currant anthocyanoside intake on dark adaptation and VDT work-induced transient refractive alteration in healthy humans, *Altern. Med. Rev.* 5 (2000) 553–562.
- [18] M.S. Chen, D. Chen, Q.P. Dou, Inhibition of proteasome activity by various fruits and vegetables is associated with cancer cell death, *In Vivo* 18 (2004) 73–80.
- [19] C. Naujokat, C. Berges, A. Höh, H. Wiczorek, D. Fuchs, J. Ovens, M. Miltz, M. Sadeghi, G. Opelz, V. Daniel, Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells, *Immunology* 120 (2006) 120–132.
- [20] P.M. Kloetzel, The proteasome and MHC class I antigen processing, *Biochim. Biophys. Acta* 1695 (2004) 217–225.
- [21] A. Visekruna, T. Joeris, D. Seidel, A. Kroesen, C. Loddenkemper, M. Zeitz, S.H. Kaufmann, R. Schmidt-Ullrich, U. Steinhoff, Proteasome-mediated degradation of I κ B α and processing of p105 in Crohn disease and ulcerative colitis, *J. Clin. Invest.* 116 (2006) 3195–3203.
- [22] N. Yamamoto, H. Sawada, Y. Izumi, T. Kume, H. Katsuki, S. Shimohama, A. Akaike, Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress—relevance to Parkinson disease, *J. Biol. Chem.* 282 (2007) 4364–4372.
- [23] A.J. Williams, J.R. Dave, F.C. Tortella, Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration, *Neurochem. Int.* 49 (2006) 106–112.
- [24] A. Nencioni, F. Grünebach, F. Patrone, A. Ballestrero, P. Brossart, Proteasome inhibitors: antitumor effects and beyond, *Leukemia* 21 (2007) 30–36.
- [25] M. Garcia-Alonso, G. Rimbach, M. Sasai, M. Nakahara, S. Matsugo, Y. Uchida, J.C. Rivas-Gonzalo, S. de Pascual-Teresa, Electron spin resonance spectroscopy studies on the free radical scavenging activity of wine anthocyanins and pyranoanthocyanins, *Mol. Nutr. Food Res.* 49 (2005) 1112–1119.
- [26] D. Marko, N. Puppel, Z. Tjaden, S. Jakobs, G. Pahlke, The substitution pattern of anthocyanidins affects different cellular signaling cascades regulating cell proliferation, *Mol. Nutr. Food Res.* 48 (2004) 318–325.
- [27] P.C. Bickford, B. Shukitt-Hale, J. Joseph, Effects of aging on cerebellar noradrenergic function and motor learning: nutritional interventions, *Mech. Ageing Dev.* 111 (1999) 141–154.
- [28] A. Saija, P. Princi, N. D'Amico, R. De Pasquale, G. Costa, Effect of *Vaccinium myrtillus* anthocyanins on triiodothyronine transport into brain in the rat, *Pharmacol. Res.* 22 (1990) 59–60.
- [29] D. Chen, K.G. Daniel, M.S. Chen, D.J. Kuhn, K.R. Landis-Piowar, Q.P. Dou, Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells, *Biochem. Pharmacol.* 69 (2005) 1421–1432.
- [30] S. Nam, D.M. Smith, Q.P. Dou, Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo, *J. Biol. Chem.* 276 (2001) 13322–13330.
- [31] A.F. Kisselev, T.N. Akopian, V. Castillo, A.L. Goldberg, Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown, *Mol. Cell* 4 (1999) 395–402.
- [32] A.J. Rivett, The multicatalytic proteinase—multiple proteolytic activities, *J. Biol. Chem.* 264 (1989) 12215–12219.
- [33] M.D. Matchett, S.L. MacKinnon, M.I. Sweeney, K.T. Gottschall-Pass, R.A. Hurta, Blueberry flavonoids inhibit matrix metalloproteinase activity in DU145 human prostate cancer cells, *Biochem. Cell Biol.* 83 (2005) 637–643.
- [34] K.A. Youdim, A. Martin, J.A. Joseph, Incorporation of the elderberry anthocyanins by endothelial cells increases protection against oxidative stress, *Free Radic. Biol. Med.* 29 (2000) 51–60.
- [35] T.K. McGhie, M.C. Walton, The bioavailability and absorption of anthocyanins: towards a better understanding, *Mol. Nutr. Food Res.* 51 (2007) 702–713.
- [36] H. Matsumoto, H. Inaba, M. Kishi, S. Tominaga, M. Hirayama, T. Tsuda, Orally administered delphinidin 3-rutinoside and cyanidin 3-rutinoside are directly absorbed in rats and humans and appear in the blood as the intact forms, *J. Agric. Food Chem.* 49 (2001) 1546–1551.
- [37] C. Andres-Lacueva, B. Shukitt-Hale, R.L. Galli, O. Jauregui, R.M. Lamuela-Raventos, J.A. Joseph, Anthocyanins in aged blueberry-fed rats are found centrally and may enhance memory, *Nutr. Neurosci.* 8 (2005) 111–120.
- [38] M.A. El Mohsen, J. Marks, G. Kuhnle, K. Moore, E. Debnam, S. Kaila Srai, C. Rice-Evans, J.P. Spencer, Absorption, tissue distribution and excretion of pelargonidin and its metabolites following oral administration to rats, *Br. J. Nutr.* 95 (2006) 51–58.
- [39] A. Milano, R.V. Iaffaioli, F. Caponigro, The proteasome: a worthwhile target for the treatment of solid tumours, *Eur. J. Cancer* 43 (2007) 1125–1133.
- [40] F.C. Lau, B. Shukitt-Hale, J.A. Joseph, The beneficial effects of fruit polyphenols on brain aging, *Neurobiol. Aging* 26S (2005) S128–S132.
- [41] N. Awasthi, B.J. Wagner, Upregulation of heat shock protein expression by proteasome inhibition: an antiapoptotic mechanism in the lens, *Invest. Ophthalmol. Vis. Sci.* 46 (2005) 2082–2091.
- [42] S. Meiners, A. Ludwig, M. Lorenz, H. Dreger, G. Baumann, V. Stangl, K. Stangl, Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells, *Free Radic. Biol. Med.* 40 (2006) 2232–2241.
- [43] M. Penkowa, J. Hidalgo, Metallothionein treatment reduces proinflammatory cytokines IL-6 and TNF- α and apoptotic cell death during experimental autoimmune encephalomyelitis (EAE), *Exp. Neurol.* 170 (2001) 1–14.
- [44] E.H.J. Yew et al., Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis, *J. Neurochem.* 94 (2005) 943–956.
- [45] A. Parcellier, S. Gurbuxani, E. Schmitt, E. Solary, C. Garrido, Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways, *Biochem. Biophys. Res. Commun.* 304 (2003) 505–512.
- [46] V. Perrin, E. Régulier, T. Abbas-Terki, R. Hassig, E. Brouillet, P. Aebischer, R. Luthi-Carter, N. Déglon, Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease, *Mol. Ther.* 15 (2007) 903–911.
- [47] B. Halliwell, Reactive oxygen species and the central nervous system, *J. Neurochem.* 59 (1992) 1609–1623.
- [48] A.M. Amorini, G. Lazzarino, F. Galvano, G. Fazzina, B. Tavazzi, G. Galvano, Cyanidin-3-O-beta-glucopyranoside protects myocardium and erythrocytes from oxygen radical-mediated damages, *Free Radic. Res.* 37 (2003) 453–460.
- [49] J. Wang, G. Mazza, Inhibitory effects of anthocyanins and other phenolic compounds on nitric oxide production in LPS/IFN-gamma-activated RAW 264.7 macrophages, *J. Agric. Food Chem.* 50 (2002) 850–857.
- [50] K.L. Rock, C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, A.L. Goldberg, Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules, *Cell* 78 (1994) 761–771.
- [51] J. Wu, On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants, *Am. J. Transplant.* 2 (2002) 904–912.
- [52] M.P. Mattson, NF- κ B in the survival and plasticity of neurons, *Neurochem. Res.* 30 (2005) 883–893.
- [53] Y. Yamamoto, R.B. Gaynor, Therapeutic potential of inhibition of the NF- κ B pathway in the treatment of inflammation and cancer, *J. Clin. Invest.* 107 (2001) 135–142.
- [54] P. Goyarzu et al., Blueberry supplemented diet: effects on object recognition memory and nuclear factor-kappa B levels in aged rats, *Nutr. Neurosci.* 7 (2004) 75–83.
- [55] H.C.A. Drexler, Activation of the cell death program by inhibition of proteasome function, *Proc. Natl. Acad. Sci. USA* 94 (1997) 855–860.